Figure 2
From: Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Comparison of OS and BCSS between for patients with cT1 triple-negative breast cancer receiving NAC and upfront surgery + AC. (A) Before PSM, overall survival; (B) Before PSM, breast cancer-specifc survival; (C) After PSM, overall survival; (D) After PSM, breast cancer-specifc survival.
